Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122387) titled 'Safety and Efficacy of SBRT Combined with a PD-1/CTLA-4 Bispecific Antibody and Chemotherapy in Recurrent/Oligometastatic Pancreatic Cancer' on April 13.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The second affiliated hospital of Zhejiang University school of medicine

Condition: Recurrent/Oligometastatic Pancreatic Cancer

Recruitment Status: Recruiting

Phase: 1

Date of First Enrollment: 2025-11-12

Target Sample Size: Experimental group:39;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=293234

Published by HT Digita...